TriangleHEALTH PROFESSIONAL · SOURCE READING
PARP inhibitor therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Metastatic Breast Cancer / Metastatic Triple-Negative Breast Cancer
Patients with TNBC and a germline BRCA pathogenic variant are eligible for PARP inhibitor therapy. For more information, see the Germline BRCA-Mutated Metastatic Breast Cancer section.
Source links and citations
Preserved source evidence · Not medical advice